Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC)

Lorraine Walsh; Charles Gillham; Mary Dunne; Ian Fraser; Donal Hollywood; John Armstrong; Pierre Thirion

doi:10.1016/j.radonc.2010.11.009

Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC)

Radiother Oncol. 2011 Jan;98(1):38-41. doi: 10.1016/j.radonc.2010.11.009. Epub 2010 Dec 13.

Authors

Lorraine Walsh¹, Charles Gillham, Mary Dunne, Ian Fraser, Donal Hollywood, John Armstrong, Pierre Thirion

Affiliation

¹ Department of Radiation Oncology, St. Luke's Hospital, Dublin, Ireland.

PMID: 21159400
DOI: 10.1016/j.radonc.2010.11.009

Abstract

We retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it with a matched cisplatin group. The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis (p=0.014), skin dermatitis (p=0.0004), ≥10% weight loss (p=0.03), and enteral feeding requirement (p=0.05). This finding of enhanced toxicity is similar to recent publications.

MeSH terms

Adult
Aged
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Carcinoma / drug therapy
Carcinoma / radiotherapy
Carcinoma, Squamous Cell
Cetuximab
Cisplatin / adverse effects*
Cisplatin / therapeutic use
Combined Modality Therapy
Female
Head and Neck Neoplasms / drug therapy
Head and Neck Neoplasms / radiotherapy
Humans
Male
Middle Aged
Neoplasms, Squamous Cell / drug therapy
Neoplasms, Squamous Cell / radiotherapy
Patient Compliance
Radiotherapy Dosage
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Cetuximab
Cisplatin